Lipella Pharmaceuticals Files 8-K
Ticker: LIPO · Form: 8-K · Filed: Feb 11, 2025 · CIK: 1347242
| Field | Detail |
|---|---|
| Company | Lipella Pharmaceuticals Inc. (LIPO) |
| Form Type | 8-K |
| Filed Date | Feb 11, 2025 |
| Risk Level | low |
| Pages | 4 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, filing, corporate-info
Related Tickers: LIPO
TL;DR
LIPO filed an 8-K, confirming Nasdaq listing and HQ address.
AI Summary
Lipella Pharmaceuticals Inc. filed an 8-K on February 11, 2025, reporting on its status as a registrant. The company's common stock trades on The Nasdaq Stock Market LLC under the ticker LIPO. The filing confirms its principal executive office is located at 7800 Susquehanna St., Suite 505, Pittsburgh, PA 15208.
Why It Matters
This 8-K filing serves as a routine update for investors, confirming the company's operational details and stock exchange listing.
Risk Assessment
Risk Level: low — This filing is a standard procedural report and does not contain new material financial or operational information that would inherently increase risk.
Key Players & Entities
- Lipella Pharmaceuticals Inc. (company) — Registrant
- February 11, 2025 (date) — Date of earliest event reported
- LIPO (stock_symbol) — Trading Symbol for Common Stock
- The Nasdaq Stock Market LLC (company) — Exchange where Common Stock is registered
- 7800 Susquehanna St., Suite 505, Pittsburgh, PA 15208 (address) — Registrant's principal executive office
FAQ
What is the primary purpose of this 8-K filing for Lipella Pharmaceuticals Inc.?
The primary purpose of this 8-K filing is to report current information as required by the SEC, including the date of the earliest event reported and confirmation of its principal executive office and stock exchange listing.
On what exchange is Lipella Pharmaceuticals Inc.'s common stock traded?
Lipella Pharmaceuticals Inc.'s common stock is traded on The Nasdaq Stock Market LLC.
What is the trading symbol for Lipella Pharmaceuticals Inc.'s common stock?
The trading symbol for Lipella Pharmaceuticals Inc.'s common stock is LIPO.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on February 11, 2025.
Where are Lipella Pharmaceuticals Inc.'s principal executive offices located?
Lipella Pharmaceuticals Inc.'s principal executive offices are located at 7800 Susquehanna St., Suite 505, Pittsburgh, PA 15208.
Filing Stats: 1,080 words · 4 min read · ~4 pages · Grade level 11.7 · Accepted 2025-02-11 09:28:38
Key Financial Figures
- $0.0001 — registered Common Stock, par value $0.0001 per share LIPO The Nasdaq Stock Mar
Filing Documents
- g084697_8-k.htm (8-K) — 38KB
- g084697_ex99-1.htm (EX-99.1) — 13KB
- g084697_ex99-2.htm (EX-99.2) — 20KB
- g084697_ex99-3.htm (EX-99.3) — 26KB
- img001_v1.jpg (GRAPHIC) — 11KB
- image_001.jpg (GRAPHIC) — 3KB
- img001_v3.jpg (GRAPHIC) — 742KB
- img002_v3.jpg (GRAPHIC) — 1125KB
- img003_v3.jpg (GRAPHIC) — 696KB
- img004_v3.jpg (GRAPHIC) — 384KB
- img005_v3.jpg (GRAPHIC) — 713KB
- img006_v3.jpg (GRAPHIC) — 617KB
- img007_v3.jpg (GRAPHIC) — 765KB
- img008_v3.jpg (GRAPHIC) — 669KB
- img009_v3.jpg (GRAPHIC) — 572KB
- img010_v3.jpg (GRAPHIC) — 594KB
- img011_v3.jpg (GRAPHIC) — 275KB
- img012_v3.jpg (GRAPHIC) — 678KB
- img013_v3.jpg (GRAPHIC) — 733KB
- img014_v3.jpg (GRAPHIC) — 387KB
- img015_v3.jpg (GRAPHIC) — 481KB
- img016_v3.jpg (GRAPHIC) — 340KB
- img017_v3.jpg (GRAPHIC) — 420KB
- img018_v3.jpg (GRAPHIC) — 522KB
- img019_v3.jpg (GRAPHIC) — 667KB
- img020_v3.jpg (GRAPHIC) — 360KB
- img021_v3.jpg (GRAPHIC) — 650KB
- img022_v3.jpg (GRAPHIC) — 668KB
- img023_v3.jpg (GRAPHIC) — 310KB
- img024_v3.jpg (GRAPHIC) — 674KB
- img025_v3.jpg (GRAPHIC) — 682KB
- img026_v3.jpg (GRAPHIC) — 723KB
- img027_v3.jpg (GRAPHIC) — 735KB
- img028_v3.jpg (GRAPHIC) — 678KB
- img029_v3.jpg (GRAPHIC) — 713KB
- img030_v3.jpg (GRAPHIC) — 448KB
- img031_v3.jpg (GRAPHIC) — 605KB
- img032_v3.jpg (GRAPHIC) — 681KB
- img033_v3.jpg (GRAPHIC) — 674KB
- img034_v3.jpg (GRAPHIC) — 689KB
- img035_v3.jpg (GRAPHIC) — 570KB
- img036_v3.jpg (GRAPHIC) — 691KB
- img037_v3.jpg (GRAPHIC) — 469KB
- img038_v3.jpg (GRAPHIC) — 569KB
- img039_v3.jpg (GRAPHIC) — 735KB
- 0001753926-25-000211.txt ( ) — 32949KB
- lipo-20250211.xsd (EX-101.SCH) — 3KB
- lipo-20250211_lab.xml (EX-101.LAB) — 33KB
- lipo-20250211_pre.xml (EX-101.PRE) — 22KB
- g084697_8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: February 11, 2025 Lipella Pharmaceuticals Inc. By: /s/ Jonathan Kaufman Name: Jonathan Kaufman Title: Chief Executive Officer